Status:
COMPLETED
Diagnostic Accuracy of the DPP II Assay
Lead Sponsor:
Foundation for Innovative New Diagnostics, Switzerland
Conditions:
Acute Febrile Illness
Melioidosis
Eligibility:
All Genders
18+ years
Brief Summary
Burkholderia pseudomallei is responsible for melioidosis, a disease that can present a range of signs and symptoms and can be treated by a specific drug regimen. Diagnosis of melioidosis is made by is...
Eligibility Criteria
Inclusion
- \- Samples that can be included in the trial must have been collected exclusively during the "Assessment of a New Rapid Diagnostic Test for Melioidosis" study (HREC 04/09) conducted by the Menzies School of Health Research. They must be well-characterized with confirmation of presence or absence of B. pseudomallei by bacterial culture.
Exclusion
- Samples with volume \<120 µL
- Samples collected during projects other than the HREC 04/09 project
Key Trial Info
Start Date :
October 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT04299412
Start Date
October 28 2019
End Date
September 30 2020
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menzies School of Health Research
Darwin, Australia